SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma gets nod to invest up to Rs 1,400 crore in NPSAPL

08 Jul 2026 Evaluate

Natco Pharma has secured approval to make an investment of up to Rs 1,400 crore in Natco Pharma South Africa Proprietary (NPSAPL), wholly owned subsidiary of the company. The Board of Directors of the company at its meeting held on July 08, 2026, has approved the same. The objective of the investment is to enter new geographies for growth and increased profitability. The investment is expected to be completed before the end of July of 2026.  NPSAPL is incorporated in South Africa for the purposes of having presence in the continent of Africa.

Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).

Natco Pharma Share Price

967.70 -16.65 (-1.69%)
08-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1887.95
Dr. Reddys Labs. 1348.70
Cipla 1431.65
Zydus Lifesciences 1149.00
Lupin 2457.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: